Drug Trial Radar · NCT05301322
Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age
Last checked: Nov 19, 2026Latest source record: Oct 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,471
Actual
Start
Apr 13, 2022
Primary completion
Oct 12, 2022
Study completion Oct 12, 2022
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Mar 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and immunogenicity of RSVpreF when coadministered with SIIV compared to sequential administration of the vaccines when given 1 month apart (SIIV followed by RSVpreF). Additionally, the study will contribute data supporting the development of RSVpreF as a prophylactic vaccine against RSV disease in infants through maternal immunization and in older adults through active vaccination.
Conditions
- Respiratory Syncytial Virus
Interventions
RSVpreF VaccineBiological
RSV Vaccine
PlaceboOther
Placebo
Seasonal Inactivated Influenza VaccineBiological
SIIV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination With RSVpreF or PlaceboTime frame: Within 7 days after Vaccination 1 or Vaccination 2
- Percentage of Participants Reporting Systemic Events Within 7 Days After Vaccination With RSVpreF or PlaceboTime frame: Within 7 days after Vaccination 1 or Vaccination 2
- Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Vaccination 1Time frame: Within 1 month after Vaccination 1
- Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Vaccination 2Time frame: Within 1 month after Vaccination 2
- Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 1 Month After Vaccination 1Time frame: Within 1 month after Vaccination 1
- Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 1 Month After Vaccination 2Time frame: Within 1 month after Vaccination 2
- Geometric Mean Ratio (GMR) of Neutralizing Titer (NTs) at 1 Month After Vaccination With RSVpreF for RSV Subfamily A and B in RSVpreF + SIIV Compared to RSVpreF AloneTime frame: 1 month after Vaccination 1 for Coadministration Group and 1 month after Vaccination 2 for Sequential-Administration Group
- GMR of the Strain-Specific Hemagglutination Inhibition (HAI) Titers 1 Month After Vaccination With SIIV in the Coadministration Group to the Corresponding HAI Titers in the Sequential-Administration GroupTime frame: 1 month after Vaccination 1
Locations
33 sites in 1 country. Site status is shown where the registry gives one.
Paratus Clinical Research Canberra
Bruce, Australian Capital Territory, Australia
Paratus Clinical Research Western Sydney
Blacktown, New South Wales, Australia
Emeritus Research
Botany, New South Wales, Australia
Genesis Research Services
Broadmeadow, New South Wales, Australia
Northern Beaches Clinical Research
Brookvale, New South Wales, Australia
Northside Health
Coffs Harbour, New South Wales, Australia
Holdsworth House Medical Practice
Darlinghurst, New South Wales, Australia
Paratus Clinical Research Central Coast
Kanwal, New South Wales, Australia
The AIM Centre / Hunter Diabetes Centre
Merewether, New South Wales, Australia
John Hunter Hospital
New Lambton Heights, New South Wales, Australia
Scientia Clinical Research
Randwick, New South Wales, Australia
Australian Clinical Research Network
Sydney, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Paratus Clinical Research Brisbane
Albion, Queensland, Australia
Core Research Group
Brisbane, Queensland, Australia
Griffith University
Gold Coast Campus, Queensland, Australia
Nucleus Network Brisbane
Herston, Queensland, Australia
Mackay Hospital and Health Service
Mackay, Queensland, Australia
USC Clinical Trials Moreton Bay
Morayfield, Queensland, Australia
USC Clinical Trials Centre
Sippy Downs, Queensland, Australia
AusTrials - Taringa
Taringa, Queensland, Australia
Core Research Group
Taringa, Queensland, Australia
AusTrials Wellers Hill
Tarragindi, Queensland, Australia
CMAX Clinical Research Pty Ltd
Adelaide, South Australia, Australia
University of Tasmania
Hobart, Tasmania, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Emeritus Research
Camberwell, Victoria, Australia
Barwon Health
Geelong, Victoria, Australia
Doctors of Ivanhoe
Ivanhoe, Victoria, Australia
Nucleus Network Brisbane
Melbourne, Victoria, Australia
Nucleus Network Melbourne
Melbourne, Victoria, Australia
Institute for Respiratory Health
Nedlands, Western Australia, Australia
Latitude Clinical Research
Spearwood, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.